In addition to NF1 GAP function, CRAF/BRAF genetic abrogation also enhances the sensitivity of NF1-MPNST cells to MEKi through sustained inhibition of ERK signaling, providing the rationale for combined type 2 RAFi with MEKi in this type of disease. The gene discussed is RAF1; the disease is malignant peripheral nerve sheath tumor.